skip to main content

Antipsychotic metabolic monitoring — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCNS TherapeuticsAntipsychotic metabolic monitoringGPhC CRA

A patient starts olanzapine and asks why the pharmacy has requested weight and glucose checks. They have a family history of type 2 diabetes. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Weight, lipids and glucose monitoring

Olanzapine is associated with weight gain, dyslipidaemia and hyperglycaemia. Baseline and follow-up metabolic monitoring supports safer use. In this scenario, the correct option is weight, lipids and glucose monitoring. The other options are plausible but do not address the key clinical, legal or safety issue as directly. This aligns with UK pharmacy practice guidance cited in the reference field.

Reference: BNF; NICE CKS